Compare TIMB & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | LNTH |
|---|---|---|
| Founded | 1998 | 1956 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 6.6B |
| IPO Year | 2020 | 2014 |
| Metric | TIMB | LNTH |
|---|---|---|
| Price | $18.88 | $100.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $25.10 | ★ $87.00 |
| AVG Volume (30 Days) | 539.9K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.91 |
| Revenue | N/A | ★ $343,374,000.00 |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $4.80 | $14.19 |
| P/E Ratio | ★ $15.81 | $34.60 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $17.14 | $49.67 |
| 52 Week High | $28.22 | $111.86 |
| Indicator | TIMB | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 45.34 |
| Support Level | $17.23 | $100.51 |
| Resistance Level | $22.74 | $101.43 |
| Average True Range (ATR) | 0.37 | 0.52 |
| MACD | 0.25 | 0.10 |
| Stochastic Oscillator | 96.30 | 38.70 |
TIM, which is 67%-owned by Telecom Italia, is the third-largest wireless carrier in Brazil, with 62 million subscribers, equal to about 23% of the market. The firm owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 8 million locations, including 6.5 million with fiber, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand, but it has agreed to buy out its joint venture partner in 2026 and will take full ownership of these assets. TIM also resells fiber network access from other providers.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.